C4 Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.
Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
Extracted from this filing and checked against the source text.
Kendra R. Adams changed role as Chief Financial Officer, Head of Corporate Affairs and Treasurer at C4 Therapeutics, Inc..
Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.View on SEC.gov
Mark Mossler departed as Chief Accounting Officer at C4 Therapeutics, Inc..
Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.